{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:33:10Z","timestamp":1792812790963,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1136\/ard-2024-225933","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T17:20:24Z","timestamp":1720459224000},"page":"1722-1730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b\/3 trials"],"prefix":"10.1016","volume":"83","clinical-trial-number":[{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04436640","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02963506","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03355573","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04436640","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02963506","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03355573","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04436640","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02963506","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03355573","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0538-8211","authenticated-orcid":false,"given":"Matthew A","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-548X","authenticated-orcid":false,"given":"Martin","family":"Rudwaleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8448-7407","authenticated-orcid":false,"given":"Floris A","family":"van Gaalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3210-4771","authenticated-orcid":false,"given":"Nigil","family":"Haroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6314-5336","authenticated-orcid":false,"given":"Lianne S","family":"Gensler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Fleurinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Marten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Massow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"de Peyrecave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"van der Horst-Bruinsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2024-225933_bib1","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","article-title":"Axial spondyloarthritis","volume":"80","author":"Navarro-Comp\u00e1n","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225933_bib2","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3899\/jrheum.170115","article-title":"The effect of anterior uveitis and previously undiagnosed spondyloarthritis: results from the DUET cohort","volume":"44","author":"O'Rourke","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2024-225933_bib3","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2019-215707","article-title":"Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts","volume":"78","author":"Boel","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225933_bib4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","article-title":"Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis","volume":"18","author":"de Winter","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2024-225933_bib5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/art.38873","article-title":"Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spotic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis","volume":"67","author":"Robinson","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225933_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","article-title":"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225933_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001108","article-title":"Characteristics and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis: a comparison by systematic literature review and meta-analysis","volume":"5","author":"L\u00f3pez-Medina","year":"2019","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-225933_bib8","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/art.24483","article-title":"The early disease stage in axial spondylarthritis: results from the German spondyloarthritis inception cohort","volume":"60","author":"Rudwaleit","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-225933_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/09273948.2011.559302","article-title":"An update on the genetics of HLA B27-associated acute anterior uveitis","volume":"19","author":"Martin","year":"2011","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1136\/ard-2024-225933_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ajo.2021.03.026","article-title":"Uveitis-related factors in patients with spondyloarthritis: treasure real-life results","volume":"228","author":"Ya\u015far Bilge","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1136\/ard-2024-225933_bib11","doi-asserted-by":"crossref","first-page":"e13572","DOI":"10.1111\/eci.13572","article-title":"Immunopathophysiology and clinical impact of uveitis in inflammatory rheumatic diseases: an update","volume":"51","author":"Hysa","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"10.1136\/ard-2024-225933_bib12","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1080\/09273948.2019.1686156","article-title":"Preliminary report on Interleukin-22, GM-CSF, and IL-17F in the pathogenesis of acute anterior uveitis","volume":"29","author":"Huang","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1136\/ard-2024-225933_bib13","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7617954","article-title":"Extra-articular symptoms in constellation with selected serum cytokines and disease activity in spondyloarthritis","volume":"2016","author":"Przepiera-B\u0119dzak","year":"2016","journal-title":"Mediat Inflamm"},{"key":"10.1136\/ard-2024-225933_bib14","article-title":"Intraocular cytokine profiling of autoimmune uveitis","volume":"75","author":"Hahn","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225933_bib15","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/ng.2007.17","article-title":"Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants","volume":"39","author":"Burton","year":"2007","journal-title":"Nat Genet"},{"key":"10.1136\/ard-2024-225933_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1167\/iovs.61.6.3","article-title":"Genomewide association study of acute anterior uveitis identifies new susceptibility loci","volume":"61","author":"Huang","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1136\/ard-2024-225933_bib17","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.22848","article-title":"Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis","volume":"68","author":"Rudwaleit","year":"2016","journal-title":"Arthrit Care Res"},{"key":"10.1136\/ard-2024-225933_bib18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.121.4.437","article-title":"Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate","volume":"121","author":"Foster","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1136\/ard-2024-225933_bib19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.2008.103192","article-title":"Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials","volume":"69","author":"Sieper","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225933_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3899\/jrheum.180312","article-title":"Reduced occurrence rate of acute anterior uveitis in Ankylosing Spondylitis treated with Golimumab \u2014 the GO-EASY study","volume":"46","author":"van Bentum","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2024-225933_bib21","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3899\/jrheum.131289","article-title":"Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis","volume":"41","author":"van Denderen","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2024-225933_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211003803","article-title":"Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study","volume":"13","author":"van der Horst-Bruinsma","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1136\/ard-2024-225933_bib23","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-225933_bib24","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225933_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225933_bib26","doi-asserted-by":"crossref","first-page":"iv79","DOI":"10.1093\/rheumatology\/keaa435","article-title":"Treatment strategies in axial spondyloarthritis: what, when and how","volume":"59","author":"Fragoulis","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"10.1136\/ard-2024-225933_bib27","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1136\/ard-2024-225933_bib28","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to Interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1136\/ard-2024-225933_bib29","article-title":"Comparative risk of incident and recurrent acute anterior uveitis across different biological agents in patients with ankylosing spondylitis","author":"Kwon","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"10.1136\/ard-2024-225933_bib30","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/annrheumdis-2021-220420","article-title":"Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter","volume":"80","author":"Lindstr\u00f6m","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225933_bib31","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"Update of the American college of rheumatology\/spondylitis association of America\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225933_bib32","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3899\/jrheum.221022","article-title":"Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program","volume":"50","author":"Deodhar","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2024-225933_bib33","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/art.42282","article-title":"Safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: three-year results from a phase IIb randomized controlled trial and its open-label extension study","volume":"74","author":"Baraliakos","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225933_bib34","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/ard-2023-224803","article-title":"Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies","volume":"83","author":"Baraliakos","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225933_bib35","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"79","author":"van der Heijde","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225933_bib36","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1136\/bjophthalmol-2018-312882","article-title":"Health-related quality of life in patients with uveitis","volume":"103","author":"Shamdas","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1136\/ard-2024-225933_bib37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/0301-4738.58468","article-title":"Current approach in diagnosis and management of anterior uveitis","volume":"58","author":"Agrawal","year":"2010","journal-title":"Indian J Ophthalmol"},{"key":"10.1136\/ard-2024-225933_bib38","first-page":"478","article-title":"Impact of uveitis on quality of life: a prospective study from a tertiary referral rheumatology-ophthalmology collaborative uveitis center in Italy","volume":"19","author":"Fabiani","year":"2017","journal-title":"Isr Med Assoc J"},{"key":"10.1136\/ard-2024-225933_bib39","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.40866","article-title":"A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225933_bib40","first-page":"26","article-title":"Acute anterior uveitis in spondyloarthritis: a monocentric study of 301 patients","volume":"37","author":"Frantz","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2024-225933_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/RHU.0000000000000869","article-title":"Clinical associations of uveitis in axial spondyloarthritis group and ankylosing spondylitis group: do they represent the same disease","volume":"26","author":"Wong","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"10.1136\/ard-2024-225933_bib42","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3109\/09273948.2013.815786","article-title":"Elevated serum levels of interleukin-17A in uveitis patients","volume":"21","author":"Jawad","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1136\/ard-2024-225933_bib43","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225933_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001306","article-title":"Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells","volume":"6","author":"Shah","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-225933_bib45","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized Igg1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2024-225933_bib46","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.immuni.2020.06.022","article-title":"The cytokine IL-17A limits TH17 pathogenicity via a negative feedback loop driven by autocrine induction of IL-24","volume":"53","author":"Chong","year":"2020","journal-title":"Immunity"},{"key":"10.1136\/ard-2024-225933_bib47","first-page":"1742","article-title":"Long-term safety and tolerability of Bimekizumab in patients with axial Spondyloarthritis and Psoriatic arthritis: results from pooled phase 2B\/3 studies","volume":"83","author":"Mease","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225933_bib48","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/ard.2007.075754","article-title":"Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review","volume":"67","author":"Zeboulon","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225933_bib49","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/acr2.11139","article-title":"Incidence of uveitis in secukinumab-treated patients with ankylosing spondylitis: pooled data analysis from three phase 3 studies","volume":"2","author":"Deodhar","year":"2020","journal-title":"ACR Open Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724665738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724665738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2024-225933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:52:14Z","timestamp":1739523134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724665738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0003496724665738"],"URL":"https:\/\/doi.org\/10.1136\/ard-2024-225933","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b\/3 trials","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2024-225933","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc on behalf of EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}